Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans to go public Friday along with Bicycle, Peloton and Ideaya.

Backed by founding investor PureTech Health plc (LSE:PRTC), Karuna Therapeutics Inc. (Boston, Mass.) has raised $122 million across two venture rounds to

Read the full 679 word article

How to gain access

Continue reading with a
two-week free trial.